[EN] SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS [FR] DÉRIVÉS SULFONYL PIPÉRIDINE ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES GASTRO-INTESTINAUX MÉDIÉS PAR LA PROKINÉTICINE
三苯基膦 、 4-氯-3-氟溴苄 以
乙醚 为溶剂,
反应 16.0h,
以to give (4-chloro-3-fluorobenzyl)-triphenylphosphonium bromide (quantitative) as a white solid that的产率得到(4-chloro-3-fluorobenzyl)-triphenylphosphonium bromide
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof
in which m, n, W, X, Y, Z, R, R
1
, R
2
, R
3
and R
4
are as defined in the specification, for use in therapy.
[EN] SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES<br/>[FR] DÉRIVÉS DE SULFONYLPIPÉRIDINE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR UNE PROKINÉTICINE
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2013179024A1
公开(公告)日:2013-12-05
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatment or prevention of a diseases o conition mediated by a prokineticin, such as psychiatric and neurological conitions.
Phenylethynyl and styryl derivatives of imidazole and fused ring heterocycles
申请人:——
公开号:US20020128263A1
公开(公告)日:2002-09-12
This invention relates to a compound and the use of the compound of the formula
1
wherein R
1
, R
2
, R
3
, R
4
and R
5
are as defined in the description, A signifies —CH═CH— or —C≡C—; and B signifies
2
wherein R
6
to R
26
, X and Y are as defined in the specification or a pharmaceutically acceptable salt thereof, for use in pharmaceutical compositions for the treatment or prevention of mGluR5 receptor mediated disorders.
[EN] 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS<br/>[FR] DÉRIVÉS DE 1-SULFONYL PIPÉRIDINE UTILISÉS EN TANT QUE MODULATEURS DES RÉCEPTEURS DE LA PROKINÉTICINE
申请人:TAKEDA CAMBRIDGE LTD
公开号:WO2014202999A1
公开(公告)日:2014-12-24
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1 , R2, R3, R4 and R5 are as defined in the specification, compositions containing them and their use in therapy.
There is provided a novel compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. The present invention provides an imidazothiazole derivative represented by the following formula (1) having various substituents that inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity:
wherein R
1
, R
2
, R
3
, R
4
, and R
5
in the formula (1) each has the same meaning as defined in the specification.